Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Galle, P. R.; Crysler, O.; Yarchoan, M.; Furuse, J.; Sukeepaisarnjaroen, W.; Thinh, N. T.; Masi, G.; Lim, H. Y.; Varela, M.; Gupta, C.; Makowsky, M.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 129 |
| Language: | English |
| ACCESSION: | WOS:001091456900277 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: V899 -- Source: Wos |
